1.Expression of perforin and granzyme-B in peripheral blood lymphocyte in patients with prostate cancer and the clinical significance.
Jingliang HE ; Liuxun LI ; Wensu WEI ; Jingchao WEI ; Zhi LONG ; Yichuan ZHANG ; Leye HE
Journal of Central South University(Medical Sciences) 2015;40(4):387-391
OBJECTIVE:
To explore the expression of perforin and granzyme-B in peripheral blood lymphocyte (PBL) in patients with prostate cancer (PCa) and the clinical significance.
METHODS:
The expressions of perforin and granzyme-B in PBL were detected by fluorescence quantitative reverse transcription polymerase chain reaction. The results of perforin and granzyme-B expression were compared among patients with PCa (n=60), patients with BPH (benign prostatic hyperplasia, n=40) and healthy controls (n=20).
RESULTS:
Th e expressions of perforin and granzyme-B in patients with PCa were significantly lower than that in patients with BPH or that in the healthy controls (P<0.05), respectively. Furthermore, in PCa patients with low pathological grade, the expressions of perforin and granzyme-B in PBL was statistically higher than that in patients with high pathological grade (P<0.05). The expressions of perforin and granzyme-B in PCa patients at high clinical stage was statistically lower than that in PCa patients at low clinical stage (P<0.05).
CONCLUSION
The results of this study suggest that development and progression of PCa might be associated with poor immune status of patients.
Case-Control Studies
;
Granzymes
;
metabolism
;
Humans
;
Lymphocytes
;
enzymology
;
Male
;
Perforin
;
metabolism
;
Prostatic Hyperplasia
;
Prostatic Neoplasms
;
immunology
2.Induction of prostate cancer-specific CTLs with dendritic cells pulsed by different types of tumor antigens.
Song XUE ; Ying-hao SUN ; Jian-ping GAO ; Xiao-feng XU ; Zheng-yu ZHANG ; Chuan-liang XU ; Xue-jun ZHU ; Zhen-fang FAN
National Journal of Andrology 2010;16(5):410-414
OBJECTIVETo study the effectiveness of freeze-thaw antigens and acid eluted peptide antigens extracted from tumor cell-pulsed dendritic cells (DC) in inducing prostate cancer-specific cytotoxic T lymphocytes (CTL) in vitro.
METHODSTumor antigens were extracted from the prostate cancer cell line PC-3 with the repeated freeze-thaw and weak acid elution methods. Peripheral blood mononuclear cells were cultured with recombinant human GM-CSF and IL-4 for inducing DCs in vitro. Then the DCs were pulsed with the two kinds of prostate cancer tumor antigens respectively and cultured with T cells for inducing CTLs. The activity of the tumor-specific CTLs were detected by LDH release assay.
RESULTSThe protein content in the tumor antigens obtained from PC-3 (2 x 10(7)) by citric acid-phosphate buffer elution and that by the repeated freeze-thaw method were (212.2 +/- 7.9) microg and (963.0 +/- 25.3) microg, respectively. The two kinds of prostate cancer antigens-pulsed DCs had a significant role in inducing the PC-3 cell-specific CTLs, and the CTLs induced by acid-eluted peptide antigen-pulsed DCs exhibited an even more significant tumor-specific cytotoxicity than those induced by repeated freeze-thaw ([60.4 +/- 5.52]% vs. [43.7 +/- 4.11]%, P < 0.01).
CONCLUSIONBoth the weak acid elution and repeated freeze-thaw methods for extracting prostate cancer antigens can be used for in vitro sensitization of DCs. The DCs pulsed by either of the two kinds of antigens can activate CTLs, and the antigens extracted by weak acid elution are even more effective.
Antigens, Neoplasm ; immunology ; Cell Line, Tumor ; Dendritic Cells ; immunology ; Humans ; Male ; Prostatic Neoplasms ; immunology ; T-Lymphocytes, Cytotoxic ; immunology
3.Tumor infiltrating dendritic cells and Mucin1 gene expression in benign prostatic hyperplasia and prostate cancer.
Song-Tao XIANG ; Si-Wei ZHOU ; Wei GUAN ; Qin-Zhang WANG ; Bao ZHANG ; Ji-Hong LIU ; Zhang-Qun YE
National Journal of Andrology 2003;9(7):497-500
OBJECTIVETo study the expression of Mucin1 gene and tumor infiltrating dendritic cells(TIDC) in the tissues of benign prostatic hyperplasia (BPH) and prostate cancer.
METHODSMucin1 and TIDC were detected in 20 specimens of BPH and 30 specimens of prostate cancer by immunohistochemistry SP method.
RESULTSMUC1 expressed in both prostate cancer and BPH. The staining patterns were significantly associated with tumor pathological grade (P < 0.001). The number of TIDC was negatively correlated with tumor pathological grade, the higher the grade, the smaller the number of TIDC (P < 0.001).
CONCLUSIONSThe expression pattern of MUC1 and the number of TIDC could be considered as useful markers to evaluate the malignant degree and prognosis of prostate cancer. The decrease of TIDC plays an important role in tumor immune evasion and immune tolerance. Highly expressed MUC1 could lead to the failure of hormonal treatment for prostate cancer, and contribute much to tumor infiltration and metastasis.
Antigens, Neoplasm ; biosynthesis ; Dendritic Cells ; immunology ; Humans ; Immunohistochemistry ; Lymphocytes, Tumor-Infiltrating ; immunology ; Male ; Mucin-1 ; Mucins ; biosynthesis ; Prostatic Hyperplasia ; immunology ; metabolism ; pathology ; Prostatic Neoplasms ; immunology ; metabolism ; pathology
4.Changes of dendritic cells in prostate cancer and dendritic cell-based immunotherapy.
Shi-yong QI ; Meng WANG ; Yong XU
National Journal of Andrology 2007;13(5):453-456
As the potent professional antigen present cell, dendritic cells (DC) play an important role in the initiation for anti-tumor immunity. Prostate cancer (PCa) can reduce the number and function of tumor infiltrated dendritic cells (TIDC) by a series of complicated mechanisms, escaping from immunosurveillance. With the development of immunology, more and more studies focus on TIDC and DC-based vaccines for PCa. However, all these studies are still at the exploratory stage. Here is a review of the related literature.
Cancer Vaccines
;
therapeutic use
;
Dendritic Cells
;
cytology
;
immunology
;
Humans
;
Immunotherapy
;
Male
;
Prostatic Neoplasms
;
immunology
;
therapy
5.Clinical efficacy and relative factors of dendritic cell-based tumor vaccination for prostate cancer: a systematic review and meta-analysis.
Kun WU ; Jun-Song MENG ; Azhati BAIHETIYA ; Yu-Jie WANG
National Journal of Andrology 2013;19(6):545-550
OBJECTIVETo evaluate the efficacy and safety of dendritic cell (DC)-based vaccines in the treatment of prostate cancer, and investigate the factors that influence the clinical benefit rate (CBR) of the vaccines.
METHODSBased on pre-determined search criteria, we searched the Medline database for randomized controlled trials on DC-based vaccines immunotherapy of prostate cancer. We systematically analyzed the identified studies using RevMan 5.0 and SPSS 17.0 softwares.
RESULTSTen randomized controlled trials involving 179 prostate cancer patients were identified and subjected to meta-analysis. The CBR of the DC vaccines for prostate cancer was 54.2% , and the objective response rate was 7.7%. Most adverse effects were local reactions at the injection site, fever and flu-like symptoms. The prostate cancer patients achieved cellular immune response (OR = 31.12, 95% CI = 5.52-175.6, P < 0.01) and reduction of log PSA slope (OR = 4.38, 95% CI = 1.17-16.35, P = 0.03) after administration of DC vaccines, which was positively correlated with CBR. The dose of DC vaccines had a significant correlation with CBR (OR = 5.98, 95% CI = 1.45-24.62, P = 0.01), but not the age of the patients (P = 0.53). Besides, density-enriched DCs achieved a higher CBR, while the route of administration had no effect on CBR.
CONCLUSIONDC-based vaccines are effective, safe and well-tolerated in the treatment of prostate cancer. DC-mediated cellular immune response has a significant effect on CBR and can be used as an important index for the assessment of vaccines. More multi-centered randomized controlled trials of higher quality and larger sample size are needed to provide more valid evidence.
Cancer Vaccines ; adverse effects ; immunology ; therapeutic use ; Dendritic Cells ; immunology ; Humans ; Male ; Prostatic Neoplasms ; prevention & control ; Randomized Controlled Trials as Topic
6.Repeated spurious elevation of serum prostate-specific antigen values solved by chemiluminescence analysis: A possible interference by heterophilic antibodies.
Arturo DOMINGUEZ ; Miquel BAYO ; Jesus MUNOZ-RODRIGUEZ ; Jose Antonio BELLIDO ; Jose Maria ABASCAL-JUNQUERA ; Naim HANNAOUI ; Josep Maria BANUS
Korean Journal of Urology 2015;56(11):785-787
Heterophilic antibodies are human immunoglobulins directed against various animal antigens. They can produce false-positive results in the analysis of different tumor markers, including prostate-specific antigen. This interference can lead to misdiagnosis, unnecessary tests, and overtreatment in some cases. We present herein the case of a 52-year-old man with repeated spurious elevation of prostate-specific antigen, reaching levels of 108.7 ng/mL, that were suspected to be caused by heterophilic antibodies. The interference was solved by changing the analysis technique. Real values of prostate-specific antigen were less than 1 ng/mL.
Antibodies, Heterophile/*immunology
;
False Positive Reactions
;
Humans
;
Luminescence
;
Male
;
Middle Aged
;
Prostate-Specific Antigen/*blood
;
Prostatic Neoplasms/blood/*diagnosis/immunology
7.Clinical significance of six-transmembrane epithelial antigen of the prostate expressed in prostatic carcinoma.
Liaoyuan LI ; Jiefang LI ; Zhoujun SHEN ; Weijun LIU ; Zhaodian CHEN
National Journal of Andrology 2004;10(5):351-354
OBJECTIVETo investigate the relationship between six-transmembrane epithelial antigen of the prostate (STEAP) expression and the histologic grading of prostatic carcinoma (PCa).
METHODSDifferent prostatic tissues and non-prostatic tumors, 131 cases of PCa, 164 cases of benign prostate hyperplasia (BPH), and 56 cases of non-prostatic malignancies, were analyzed for the expression of STEAP by using STEAP monoclonal antibody and SP immunohistochemical staining. The positive area unit (PU) was introduced to describe the intensity of STEAP expression.
RESULTSThe prostatic tissues of all but 3 cases of PCa and 5 cases of BPH were stained positively, while all of the non-prostatic tumors were stained negatively. There was a significant negative correlation between the STEAP expression and the histologic grading of PCa.
CONCLUSIONSTEAP can be a prognostic marker of PCa and a potential therapeutic target in PCa.
Antigens, Neoplasm ; analysis ; genetics ; Humans ; Immunohistochemistry ; Male ; Oxidoreductases ; Prostatic Neoplasms ; diagnosis ; immunology ; pathology
8.Serum p2PSA derivative indexes in prostate cancer: an update.
National Journal of Andrology 2015;21(1):74-77
Serum prostate-specific antigen (PSA) is composed of the PSA precursor protein (proPSA) in the absence of the leader peptide induced by human kallikrein 2 (hK2). There are many forms of PSA in the blood, including free PSA and bound PSA. Serum proPSA, as a free PSA, has many isoforms, among which, [-2]proPSA (p2PSA) cannot be activated by hK2 and therefore exists stably in the blood. Serum p2PSA is a homologous isomer of PSA. Serum prostate health index and % p2PSA, as the derivative indexes of p2PSA and molecular markers associated with the development and progression of prostate cancer, can reduce serum PSA test-induced excessive diagnosis and treatment of the malignancy and improve the accuracy of its prediction. This review summarizes recent progress in the studies of serum p2PSA and its derivative indexes in prostate cancer.
Humans
;
Male
;
Prostate-Specific Antigen
;
blood
;
Prostatic Neoplasms
;
blood
;
immunology
;
Protein Isoforms
;
blood
9.Prostate stem cell antigen and related cancers.
National Journal of Andrology 2004;10(5):382-384
Prostate stem cell antigen (PSCA) is a cell surface antigen expressed in normal prostate and overexpressed in cancers associated with prostate, bladder and pancreas. The sensitivity of PSCA labeling is higher than PSA in prostate cancer. PSCA can be used in the preparation of protein vaccine and nucleic acid vaccine. Further studies are required to confirm its safety and efficacy as a diagnostic means.
Antigens, Neoplasm
;
GPI-Linked Proteins
;
Humans
;
Immunotherapy
;
Male
;
Membrane Glycoproteins
;
analysis
;
genetics
;
immunology
;
Neoplasm Proteins
;
analysis
;
genetics
;
immunology
;
Pancreatic Neoplasms
;
diagnosis
;
Prostatic Neoplasms
;
diagnosis
;
Urinary Bladder Neoplasms
;
diagnosis
10.Comparison of biologic activity of two anti-PSA/anti-CD3 bispecific single-chain antibodies.
Dong WANG ; Guo-jun WU ; He WANG ; Wei-zhen WU ; Shun-liang YANG ; Jian-ming TAN
National Journal of Andrology 2007;13(1):8-12
OBJECTIVETo study and compare the biologic activity of two anti-PSA/anti-CD3 bispecific single-chain antibodies.
METHODSFlow cytometry (FCM) was used to detect the binding activity of two antibodies to CD3-positive cell line Jurkat and prostate carcinoma cell line LNCaP. The effect of the two antibodies in mediating tumor cell lysis in vitro was determined by using the 51Cr-release test. For in vivo evaluation of the two antibodies activity, a nude mouse model was used. The mice were inoculated with LNCaP prostate cancer cells.
RESULTSFCM showed that both the antibodies could bind Jurkat and LNCaP cells with high specificity. The percentages of the cells bond by the bispecific single-chain antibodies were 56.3% and 55.4%, and those by the multivalent antibodies were 74.0% and 83.0% respectively. Both the antibodies mediated a specific lysis of LNCaP cells in vitro, with activated CTLs as effector cells, and significantly reduced tumor growth of nude mice in vivo as compared with the untreated controls and the group treated with CTLs only (P <0.05). The experiment also showed that the multivalent antibody had a better activity than the bispecific antibody in binding antigens, mediating lysis of LNCaP cells and reducing tumor growth (P < 0.05).
CONCLUSIONBoth the anti-PSA/anti-CD3 bispecific single-chain antibody and multivalent antibody have good biologic activity, and the formation of the tetramerization of single-chain antibody can improve its biologic activity.
Animals ; Antibodies, Anti-Idiotypic ; immunology ; Antibodies, Bispecific ; immunology ; pharmacology ; CD3 Complex ; immunology ; Cytotoxicity, Immunologic ; immunology ; Flow Cytometry ; Humans ; Jurkat Cells ; Male ; Mice ; Mice, Nude ; Prostate-Specific Antigen ; immunology ; Prostatic Neoplasms ; immunology ; pathology